Indivior (NASDAQ:INDV) announced on Tuesday that it is exploring strategic options for its nasal opioid overdose treatment, Opvee, as well as its international operations. In a recent filing, the ...
Indivior PLC is set to report fourth-quarter and full-year 2025 results before the market opens Thursday, February 26, as Wall Street looks for evidence the addiction-treatment specialist can deliver ...
Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net ...
13don MSN
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program
Q4 2025 Management View CEO Joseph Ciaffoni stated that 2025 was a transition year, highlighting the successful completion of Phase I Generate Momentum and the delivery of record net revenue for ...
Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. According ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results